Skip to main content

Table 2 Correlation of nucleus and cytoplasmic ERβ2 and ERβ5 with clinicopathological parameters in ovarian cancer

From: Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis

Characteristics

Case (n)

Nucleus ERβ2

Cytoplasmic ERβ2

 

Nucleus ERβ5

 

Cytoplasmic ERβ5

 
  

Mean ± SD

p-value

Mean ± SD

p-value

 

Mean ± SD

p-value

 

Mean ± SD

p-value

 

Stage (FIGO)

 Early (I-II)

49

5.46 ± 1.50

 

3.90 ± 1.43

  

6.61 ± 1.10

  

1.86 ± 1.67

  

 Late (III-IV)

37

5.65 ± 1.60

0.936*

3.78 ± 1.40

0.701*

 

7.11 ± 1.22

0.030 *

1.46 ± 1.77

0.165*

 

Histological grade

 Low (1–2)

56

5.49 ± 1.76

 

3.84 ± 1.58

  

6.88 ± 1.06

  

1.70 ± 1.72

  

 High (3)

33

5.64 ± 1.27

0.996*

3.88 ± 1.32

0.784*

 

6.82 ± 1.29

0.751*

 

1.67 ± 1.80

0.904*

 

Histology

 Serous

35

5.80 ± 1.68

 

4.06 ± 1.24

  

6.89 ± 1.37

  

1.40 ± 1.77

  

 Clear Cell

17

5.71 ± 1.26

 

3.00 ± 2.00

  

7.29 ± 1.11

  

1.06 ± 1.44

  

 Mucinous

9

4.63 ± 2.26

 

3.25 ± 1.49

  

6.22 ± 0.67

  

1.78 ± 1.64

  

 Endometrioid

29

5.40 ± 1.35

0.608

4.27 ± 1.14

0.005

 

6.70 ± 0.92

0.079

 

2.33 ± 1.73

0.071

 

 Serous/Clear Cell

52

5.77 ± 1.54

 

3.71 ± 1.59

  

7.02 ± 1.29

  

1.29 ± 1.66

  

 Mucinous/Endometrioid

38

5.24 ± 1.58

0.237*

4.05 ± 1.27

0.246*

 

6.59 ± 0.88

0.039 *

2.21 ± 1.70

0.013 *

 Clear Cell

17

5.71 ± 1.26

 

3.00 ± 2.00

  

7.29 ± 1.11

  

1.06 ± 1.44

  

 Non-Clear Cell

73

5.51 ± 1.64

0.580*

4.05 ± 1.25

0.001 *

6.73 ± 1.14

0.095*

 

1.82 ± 1.77

0.134*

 

Chemosensitivitya

 Sensitive

63

5.56 ± 1.57

 

3.64 ± 1.36

  

6.84 ± 1.13

  

1.67 ± 1.72

  

 Resistant

13

5.92 ± 1.38

0.595*

4.46 ± 1.66

0.105*

 

6.92 ± 1.12

0.387*

 

1.69 ± 1.93

0.846*

 
  1. Those with significant P-values are underlined. ↑Increase expression. ↓Decrease expression
  2. *Mann–Whitney test; Kruskal–Wallis rank test
  3. aChemosensitive-patients remained disease free more than 6 months after completion of first-line chemotherapy
  4. Intensity values are expressed as “Histoscores” as specified in Methods